Search results
Showing 1081 to 1095 of 9025 results
Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)
Evidence-based recommendations on ponesimod (Ponvory) for treating relapsing–remitting multiple sclerosis in adults.
Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.
View recommendations for TA223Show all sections
Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)
Evidence-based recommendations on bevacizumab gamma (Lytenava) for treating wet age-related macular degeneration in adults.
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)
Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.
View recommendations for TA217Show all sections
Evidence-based recommendations on azacitidine (Vidaza) for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia in adults.
Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)
Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune thrombocytopenia in adults.
Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)
Evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in adults.
Agomelatine for the treatment of major depressive episodes (terminated appraisal) (TA231)
NICE is unable to recommend the use in the NHS of agomelatine for the treatment of major depressive episodes. This is because Servier did not provide an evidence submission.
Show all sections
Sections for TA231
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma (TA226)
Evidence-based recommendations on rituximab (MabThera) for the maintenance treatment of follicular non-Hodgkin’s lymphoma in adults.
Evidence-based recommendations on mifamurtide (Mepact) for treating osteosarcoma in people aged 2 to 30 years.
Ticagrelor for the treatment of acute coronary syndromes (TA236)
Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes in adults.
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)
Evidence-based recommendations on tocilizumab (RoActemra), for treating systemic juvenile idiopathic arthritis in people aged 2 and over.
Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)
Evidence-based recommendations on fulvestrant (Faslodex), for treating locally advanced or metastatic breast cancer in adults.
Ublituximab for treating relapsing multiple sclerosis (TA1025)
Evidence-based recommendations on ublituximab (Briumvi) for treating relapsing multiple sclerosis in adults.
Evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.
Show all sections